Deltec Asset Management LLC lifted its stake in Ocular Therapeutix Inc (NASDAQ:OCUL) by 16.3% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 619,945 shares of the biopharmaceutical company’s stock after purchasing an additional 86,959 shares during the period. Deltec Asset Management LLC owned 1.61% of Ocular Therapeutix worth $4,266,000 as of its most recent SEC filing.
Other large investors also recently bought and sold shares of the company. GSA Capital Partners LLP bought a new stake in Ocular Therapeutix during the 1st quarter valued at about $102,000. MetLife Investment Advisors LLC bought a new stake in shares of Ocular Therapeutix in the second quarter worth approximately $117,000. The Manufacturers Life Insurance Company grew its stake in shares of Ocular Therapeutix by 328.4% in the first quarter. The Manufacturers Life Insurance Company now owns 24,123 shares of the biopharmaceutical company’s stock worth $157,000 after acquiring an additional 18,492 shares during the period. Barclays PLC grew its stake in shares of Ocular Therapeutix by 587.0% in the first quarter. Barclays PLC now owns 28,262 shares of the biopharmaceutical company’s stock worth $184,000 after acquiring an additional 24,148 shares during the period. Finally, Millennium Management LLC grew its stake in shares of Ocular Therapeutix by 91.0% in the first quarter. Millennium Management LLC now owns 42,369 shares of the biopharmaceutical company’s stock worth $276,000 after acquiring an additional 20,192 shares during the period. 56.65% of the stock is owned by hedge funds and other institutional investors.
In other news, CFO Donald Notman purchased 12,500 shares of the stock in a transaction on Tuesday, August 14th. The shares were acquired at an average price of $6.29 per share, with a total value of $78,625.00. Following the completion of the acquisition, the chief financial officer now directly owns 17,300 shares of the company’s stock, valued at $108,817. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Antony C. Mattessich purchased 16,900 shares of the stock in a transaction on Friday, August 10th. The shares were purchased at an average cost of $6.23 per share, for a total transaction of $105,287.00. Following the acquisition, the insider now directly owns 37,900 shares of the company’s stock, valued at $236,117. The disclosure for this purchase can be found here. Insiders have purchased 49,400 shares of company stock valued at $302,912 over the last 90 days. 15.90% of the stock is currently owned by company insiders.
NASDAQ OCUL traded down $0.18 during trading hours on Thursday, hitting $6.19. 3,140 shares of the company’s stock traded hands, compared to its average volume of 408,252. The company has a current ratio of 4.92, a quick ratio of 4.91 and a debt-to-equity ratio of 0.21. The firm has a market capitalization of $265.51 million, a price-to-earnings ratio of -2.85 and a beta of 1.21. Ocular Therapeutix Inc has a 52 week low of $3.30 and a 52 week high of $8.28.
Ocular Therapeutix (NASDAQ:OCUL) last announced its earnings results on Tuesday, August 7th. The biopharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.37). The company had revenue of $0.65 million during the quarter, compared to analyst estimates of $0.35 million. Ocular Therapeutix had a negative net margin of 2,814.72% and a negative return on equity of 143.32%. Sell-side analysts predict that Ocular Therapeutix Inc will post -1.53 EPS for the current year.
OCUL has been the subject of a number of research analyst reports. Cantor Fitzgerald set a $22.00 price target on shares of Ocular Therapeutix and gave the stock a “buy” rating in a research note on Wednesday, October 3rd. BidaskClub upgraded shares of Ocular Therapeutix from a “sell” rating to a “hold” rating in a research note on Thursday, September 27th. Zacks Investment Research lowered shares of Ocular Therapeutix from a “buy” rating to a “hold” rating in a research note on Wednesday, July 25th. ValuEngine lowered shares of Ocular Therapeutix from a “hold” rating to a “sell” rating in a research note on Friday, September 14th. Finally, JMP Securities reiterated a “buy” rating and issued a $9.00 price target on shares of Ocular Therapeutix in a research note on Thursday, October 11th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and six have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $12.00.
Ocular Therapeutix Profile
Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel platform technology. Its lead product candidates include DEXTENZA (dexamethasone insert) for the treatment of post-surgical ocular pain and inflammation, allergic conjunctivitis, and dry eye diseases; and OTX-TP (travoprost insert) for the reduction of intraocular pressure (IOP) in patients with glaucoma and ocular hypertension.
Featured Article: Can individual investors take part in an IPO?
Want to see what other hedge funds are holding OCUL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ocular Therapeutix Inc (NASDAQ:OCUL).
Receive News & Ratings for Ocular Therapeutix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocular Therapeutix and related companies with MarketBeat.com's FREE daily email newsletter.